Intraocular corticosteroids for posterior segment disease: 2012 update

Expert Opinion on Pharmacotherapy

Volumn 13, Issue 12, 2012, Pages 1679-1694

  Kiernan, Daniel F ^a   Mieler, William F ^b  

^a OPHTHALMIC CONSULTANTS OF LONG ISLAND   (United States)

^b UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

Author keywords

Choroidal neovascularization (CNV); Clinical trials; Cystoid macular edema (CME); Dexamethasone; Diabetic macular edema (DME); Fluocinolone acetonide; Intravitreal implant; Posterior uveitis; Retinal vein occlusion; Triamcinolone acetonide

Indexed keywords

CORTICOSTEROID; DEXAMETHASONE; FLUOCINOLONE; FLUOCINOLONE ACETONIDE; PEGAPTANIB; PLACEBO; RANIBIZUMAB; TRIAMCINOLONE; TRIAMCINOLONE ACETONIDE; VERTEPORFIN;

BRANCH RETINAL VEIN OCCLUSION; CENTRAL RETINA VEIN OCCLUSION; CLINICAL TRIAL (TOPIC); CONJUNCTIVAL HEMORRHAGE; DIABETIC MACULAR EDEMA; DRUG EFFICACY; DRUG SAFETY; HUMAN; IMPLANT; IN VITRO STUDY; INTRAOCULAR HYPERTENSION; INTRAOCULAR IMPLANT; LASER COAGULATION; NONHUMAN; PHOTODYNAMIC THERAPY; RETINA BLOOD VESSEL OCCLUSION; RETINA MACULA AGE RELATED DEGENERATION; RETINA MACULA CYSTOID EDEMA; RETINA MACULA EDEMA; REVIEW; SINGLE DRUG DOSE; SUBCONJUNCTIVAL HEMORRHAGE; SYMPATHETIC OPHTHALMIA; TEMPORAL ARTERITIS; UVEITIS; VITREORETINOPATHY; VITREOUS HEMORRHAGE;

ADRENAL CORTEX HORMONES; ANIMALS; DRUG IMPLANTS; EYE DISEASES; HUMANS; INTRAVITREAL INJECTIONS;

EID: 84864058031     PISSN: 14656566     EISSN: 17447666     Source Type: Journal    
DOI: 10.1517/14656566.2012.690736     Document Type: Review

References (103)

1. Grossniklaus HE, Ling JX, Wallace TM, et al. Macrophage and retinal pigment epithelium expression of angiogenic cytokines in choroidal neovascularization. Mol Vis 2002;21:119-126
2. Bhutto IA, McLeod DS, Hasegawa T, et al. Pigment epithelium-derived factor (PEDF) and vascular endothelial growth factor (VEGF) in aged human choroids and eyes with age-related macular degeneration. Exp Eye Res 2006;82:99-110
3. Kreines K, Weinberg IC. The selection of adrenocorticosteroid preparations. Ohio State Med J 1975;71:698; 703-6
4. Nauck M, Karakiulakis G, Perruchoud A, et al. Corticosteroids inhibit the expression of the vascular endothelial growth factor gene in human vascular smooth muscle cells. Eur J Pharmacol 1998;341:309-315
5. Crum R, Szabo S, Folkman J. A new class of steroids inhibits angiogenesis in the presence of heparin or a heparin fragment. Science 1985;230:1375-1378
6. Duguid IG, Boyd AW, Mandel TE. Adhesion molecules are expressed in the human retina and choroid. Curr Eye Res 1992;11(Suppl):153-159
7. Jaffe GJ, Martin D, Callanan D, et al. Fluocinolone Acetonide Uveitis Study Group. Fluocinolone acetonide implant (Retisert) for noninfectious posterior uveitis: Thirty-four week results of a multicenter randomized clinical study. Ophthalmology 2006;113:1020-1027
8. Jermak CM, Dellacroce JT, Heffez J, Peyman GA. Triamcinolone acetonide in ocular therapeutics. Surv Ophthalmol 2007;52(5):503-522
9. Andrade RE, Muccioli C, Farah ME, et al. Intravitreal triamcinolone in the treatment of serous retinal detachment in Vogt-Koyanagi-Harada syndrome. Am J Ophthalmol 2004;137:572-574
10. Francis BA, Chang EL, Haik BG. Particle size and drug interactions of injectable corticosteroids used in ophthalmic practice. Ophthalmology 1996;103:1884-1888
11. Gillies MC, Sutter FK, Simpson JM, et al. Intravitreal triamcinolone for refractory diabetic macular edema: Two-year results of a double-masked, placebo-controlled, randomized clinical trial. Ophthalmology 2006;113(9):1533-1538
12. Jonas JB, Kamppeter BA, Harder B, et al. Intravitreal triamcinolone acetonide for diabetic macular edema: A prospective, randomized study. J Ocul Pharmacol Ther 2006;22:200-207
13. Dehghan MH, Ahmadieh H, Ramezani A, et al. A randomized, placebo-controlled clinical trial of intravitreal triamcinolone for refractory diabetic macular edema. Int Ophthalmol 2008;28:7-17
14. Cardillo JA, Melo LA Jr, Costa RA, et al. Comparison of intravitreal versus posterior sub-Tenon's capsule injection of triamcinolone acetonide for diffuse diabetic macular edema. Ophthalmology 2005;112:1557-1563
15. Yilmaz T, Weaver CD, Gallagher MJ, et al. Intravitreal triamcinolone acetonide injection for treatment of refractory diabetic macular edema: A systematic review. Ophthalmology 2009;116(5):902-911
16. Beck RW, Edwards AR, Aiello LP, et al. Diabetic Retinopathy Clinical Research Network (DRCR.net). Three-year follow-up of a randomized trial comparing focal/grid photocoagulation and intravitreal triamcinolone for diabetic macular edema. Arch Ophthalmol 2009;127(3):245-251
17. Elman MJ, Bressler NM, Qin H, et al. Diabetic Retinopathy Clinical Research Network. Expanded 2-year follow-up of ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema. Ophthalmology 2011;118(4):609-14
18. Rajendram R, Fraser-Bell S, Kaines A, et al. A 2-year prospective randomized controlled trial of intravitreal Bevacizumab or Laser Therapy (BOLT) in the management of diabetic macular edema: 24-month data: Report 3. Arch Ophthalmol 2012; published ahead of print
19. Nguyen QD, Brown DM, Marcus DM; RISE and RIDE Research Group. Ranibizumab for diabetic macular edema: Results from 2 phase III randomized trials: Rise and RIDE. Ophthalmology 2012;119(4):789-801
20. Boscia F, Furino C, Dammacco R, et al. Intravitreal triamcinolone acetonide in refractory pseudophakic cystoid macular edema: Functional and anatomic results. Eur J Ophthalmol 2005;15(1):89-95
21. Benhamou N, Massin P, Haouchine B, et al. Intravitreal triamcinolone for refractory pseudophakic macular edema. Am J Ophthalmol 2003;135(2):246-249
22. Koutsandrea C, Moschos MM, Brouzas D, et al. Intraocular triamcinolone acetonide for pseudophakic cystoid macular edema: Optical coherence tomography and multifocal electroretinography study. Retina 2007;27(2):159-164
23. Jonas JB, Kreissig I, Degenring RF. Intravitreal triamcinolone acetonide for pseudophakic cystoid macular edema. Am J Ophthalmol 2003;136(2):384-386
24. Conway MD, Canakis C, Livir-Rallatos C, Peyman GA. Intravitreal triamcinolone acetonide for refractory chronic pseudophakic cystoid macular edema. J Cataract Refract Surg 2003;29(1):27-33
25. Karacorlu M, Ozdemir H, Karacorlu S. Intravitreal triamcinolone acetonide for the treatment of chronic pseudophakic cystoid macular oedema. Acta Ophthalmol Scand 2003;81(6):648-652
26. Hayreh SS. Prevalent misconceptions about acute retinal vascular occlusive disorders. Prog Retin Eye Res 2005;24(4):493-519
27. McAllister IL, Vijayasekaran S, Chen SD, Yu DY. Effect of triamcinolone acetonide on vascular endothelial growth factor and occludin levels in branch retinal vein occlusion. Am J Ophthalmol 2009;147(5):838-46; 846.e1-2
28. Engler CB, Sander B, Larsen M, et al. Probenecid inhibition of the outward transport of fluorescein across the human blood-retinal barrier. Acta Ophthalmologica (Copenh) 1994;72:663-667
29. Cheng KC, Wu WC, Lin CJ. Intravitreal triamcinolone acetonide for patients with macular oedema due to central retinal vein occlusion in Taiwan. Eye 2009;23(4):849-857
30. Krepler K, Ergun E, Sacu S, et al. Intravitreal triamcinolone acetonide in patients with macular oedema due to central retinal vein occlusion. Acta Ophthalmol Scand 2005;83(1):71-75
31. Ip MS, Gottlieb JL, Kahana A, et al. Intravitreal triamcinolone for the treatment of macular edema associated with central retinal vein occlusion. Arch Ophthalmol 2004;122:1131-1136
32. Cakir M, Dogan M, Bayraktar Z, et al. Efficacy of intravitreal triamcinolone for the treatment of macular edema secondary to branch retinal vein occlusion in eyes with or without grid laser photocoagulation. Retina 2008;28(3):465-472
33. Chen SD, Sundaram V, Lochhead J, Patel CK. Intravitreal triamcinolone for the treatment of ischemic macular edema associated with branch retinal vein occlusion. Am J Ophthalmol 2006;141(5):876-883
34. Ozkiris A, Evereklioglu C, Erkilic K, Dogan H. Intravitreal triamcinolone acetonide for treatment of persistent macular oedema in branch retinal vein occlusion. Eye 2006;20(1):13-17
35. Ip MS, Scott IU, VanVeldhuisen PC, et al. SCORE Study Research Group. A randomized trial comparing the efficacy and safety of intravitreal triamcinolone with observation to treat vision loss associated with macular edema secondary to central retinal vein occlusion: The Standard Care vs Corticosteroid for Retinal Vein Occlusion (SCORE) study report 5. Arch Ophthalmol 2009;127(9):1101-1114
36. Scott IU, Ip MS, VanVeldhuisen PC, et al. SCORE Study Research Group. A randomized trial comparing the efficacy and safety of intravitreal triamcinolone with standard care to treat vision loss associated with macular Edema secondary to branch retinal vein occlusion: The Standard Care vs Corticosteroid for Retinal Vein Occlusion (SCORE) study report 6. Arch Ophthalmol 2009;127(9):1115-1128
37. Nowak JZ. Age-related macular degeneration (AMD): Pathogenesis and therapy. Pharmacol Rep 2006;58(3):353-363
38. Jonas JB. Intravitreal triamcinolone acetonide: A change in a paradigm. Ophthalmic Res 2006;38:218-245
39. Jager RD, Mieler WF, Miller JW. Age-related macular degeneration. N Engl J Med 2008;358(24):2606-2617
40. Penfold PL, Wen L, Madigan MC, et al. Triamcinolone acetonide modulates permeability and intercellular adhesion molecule-1 (ICAM-1) expression of the ECV304 cell line: Implications for macular degeneration. Clin Exp Immunol 2000;121:458-465
41. Penfold PL, Wen L, Madigan MC, et al. Modulation of permeability and adhesion molecule expression by human choroidal endothelial cells. Invest Ophthalmol Vis Sci 2002;43:3125-3130
42. Ciulla TA, Chriswell MH, Danis RP, Hill TE. Intravitreal triamcinolone acetonide inhibits choroidal neovascularization in a laser-treated rat model. Arch Ophthalmol 2001;119:399-404
43. Jonas JB, Kreissig I, Degenring RF. Neovascular glaucoma treated by intravitreal triamcinolone acetonide. Acta Ophthalmol 2003;81:540-541
44. Danis RP, Bingaman DP, Yang Y, Ladd B. Inhibition of preretinal and optic nerve head neovascularization in pigs by intravitreal triamcinolone acetonide. Ophthalmology 1996;103:2099-2104
45. Penfold PL, Wong JG, Gyory J, Billson FA. Effects of triamcinolone acetonide on microglial morphology and quantitative expression of MHC-II in exudative age-related macular degeneration. Clin Experiment Ophthalmol 2001;29:188-192
46. Danis RP, Ciulla TA, Pratt LM, Anliker W. Intravitreal triamcinolone acetonide in exudative age-related macular degeneration. Retina 2000;20:244-250
47. Jonas JB, Kreissig I, Degenring RF. Repeated intravitreal injections of triamcinolone acetonide as treatment of progressive exudative age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol 2002;240:873-874
48. Jonas JB, Akkoyun I, Budde WM, et al. Intravitreal re-injection of triamcinolone for exudative age-related macular degeneration. Arch Ophthalmol 2004;122:218-222
49. Jonas JB, Kreissig I, Degenring RF. Factors influencing visual acuity after intravitreal triamcinolone acetonide as treatment of exudative age-related macular degeneration. Br J Ophthalmol 2004;88:1557-1562
50. Jonas JB, Spandau UH, Harder B, et al. Inter-eye difference in exudative age-related macular degeneration with minimally classic or occult subfoveal neovascularization after unilateral intravitreal injection of triamcinolone acetonide. Am J Ophthalmol 2005;139:1073-1079
51. Ranson NT, Danis RP, Ciulla TA, et al. Intravitreal triamcinolone in subfoveal recurrence of choroidal neovascularization after laser treatment in macular degeneration. Br J Ophthalmol 2002;86:527-529
52. Kreines K, Weinberg IC. The selection of adrenocorticosteroid preparations. Ohio State Med J 1975;71:698; 703-6
53. Augustin AJ, Schmidt-Erfurth U. Verteporfin therapy combined with intravitreal triamcinolone in all types of choroidal neovascularization due to age-related macular degeneration. Ophthalmology 2006;113:14-22
54. Wang K, Wang Y, Gao L, et al. Dexamethasone inhibits leukocyte accumulation and vascular permeability in retina of streptozotocin-induced diabetic rats via reducing vascular endothelial growth factor and intercellular adhesion molecule-1 expression. Biol Pharm Bull 2008;31(8):1541-1546
55. Edelman JL, Lutz D, Castro MR. Corticosteroids inhibit VEGF-induced vascular leakage in a rabbit model of blood-retinal and blood-aqueous barrier breakdown. Exp Eye Res 2005;80:249-258
56. Heier JS, Boyer DS, Ciulla TA, et al. FOCUS Study Group. Ranibizumab combined with verteporfin photodynamic therapy in neovascular age-related macular degeneration: Year 1 results of the FOCUS Study. Arch Ophthalmol 2006;124(11):1532-1542
57. Spaide RF, Sorenson J, Maranan L. Photodynamic therapy with verteporfin combined with intravitreal injection of triamcinolone acetonide for choroidal neo-vascularization. Ophthalmology 2005;112:301-304
58. Bakri SJ, Couch SM, McCannel CA, Edwards AO. Same-day triple therapy with photodynamic therapy, intravitreal dexamethasone, and bevacizumab in wet age-related macular degeneration. Retina 2009;29(5):573-578
59. Liggett PE, Colina J, Chaudhry NA, et al. Triple therapy of intravitreal triamcinolone, photodynamic therapy, and pegaptanib sodium for choroidal neovascularization. Am J Ophthalmol 2006;142(6):1072-1074
60. Arroyo JG, Michaud N, Jakobiec FA. Choroidal neovascular membranes treated with photodynamic therapy. Arch Ophthalmol 2003;121:898-903
61. Krammer B. Vascular effects of photodynamic therapy. Anticancer Res 2001;21:4271-4277
62. Rechtman E, Danis RP, Pratt LM, Harris A. Intravitreal triamcinolone with photodynamic therapy for subfoveal choroidal neovascularization in age related macular degeneration. Br J Ophthalmol 2004;88:344-347
63. Chaudhary V, Mao A, Hooper PL, Sheidow TG. Triamcinolone acetonide as adjunctive treatment to verteporfin in neovascular age-related macular degeneration: A prospective randomized trial. Ophthalmology 2007;114(12):2183- 2189
64. Kaiser P.K. Boyer D.S. Cruess A.F. et al. DENALI Study Group. Verteporfin plus ranibizumab for choroidal neovascularization in age-related macular degeneration: Twelve-month results of the DENALI study Ophthalmology 2012; Published Ahead of Print
65. Rodrigues EB, Maia M, Meyer CH, et al. Vital dyes for chromovitrectomy. Curr Opin Ophthalmol 2007;18(3):179-187
66. Furino C, Micelli Ferrari T, Boscia F, et al. Triamcinolone-assisted pars plana vitrectomy for proliferative vitreoretinopathy. Retina 2003;23(6):771-776
67. Tognetto D, Zenoni S, Sanguinetti G, et al. Staining of the internal limiting membrane with intravitreal triamcinolone acetonide. Retina 2005;25(4):462-467
68. Horio N, Horiguchi M, Yamamoto N. Triamcinolone-assisted internal limiting membrane peeling during idiopathic macular hole surgery. Arch Ophthalmol 2005;123(1):96-99
69. Triesence-Drug information. Available from: Http://www.alconretina.com/ products/triesence.asp [Last accessed 11 December 2011]
70. Moshfeghi AA, Nugent AK, Nomoto H, et al. Triamcinolone acetonide preparations: Impact of crystal size on in vitro behavior. Retina 2009;29(5):689-698
71. Dyer D, Callanan D, Bochow T, et al. Clinical evaluation of the safety and efficacy of preservative-free triamcinolone (triesence [triamcinolone acetonide injectable suspension] 40 mg/ml) for visualization during pars plana vitrectomy. Retina 2009;29(1):38-45
72. Arbisser LB, Charles S, Howcroft M, Werner L. Management of vitreous loss and dropped nucleus during cataract surgery. Ophthalmol Clin North Am 2006;19(4):495-506
73. Bourges JL, Bloquel C, Thomas A, et al. Intraocular implants for extended drug delivery: Therapeutic applications. Adv Drug Deliv Rev 2006;58(11):1182-1202
74. Lim JI, Wolitz RA, Dowling AH, et al. Visual and anatomic outcomes associated with posterior segment complications after ganciclovir implant procedures in patients with AIDS and cytomegalovirus retinitis. Am J Ophthalmol 1999;127(3):288-293
75. Driot JY, Novack GD, Rittenhouse KD, et al. Ocular pharmacokinetics of fluocinolone acetonide after Retisert intravitreal implantation in rabbits over a 1-year period. J Ocul Pharmacol Ther 2004;20(3):269-275
76. Jaffe GJ, Yang CH, Guo H, et al. Safety and pharmacokinetics of an intraocular fluocinolone acetonide sustained delivery device. Invest Ophthalmol Vis Sci 2000;41(11):3569-3575
77. Mruthyunjaya P, Khalatbari D, Yang P, et al. Efficacy of low-release-rate fluocinolone acetonide intravitreal implants to treat experimental uveitis. Arch Ophthalmol 2006;124(7):1012-1018
78. Jaffe GJ, McCallum RM, Branchaud B, et al. Long-term follow-up results of a pilot trial of a fluocinolone acetonide implant to treat posterior uveitis. Ophthalmology 2005;112(7):1192-1198
79. Retisert (fluocinolone acetonide intravitreal implant) formulary kit. Bausch & Lomb; Rochester, NY: 2005
80. Callanan DG, Jaffe GJ, Martin DF, et al. Treatment of posterior uveitis with a fluocinolone acetonide implant: Three-year clinical trial results. Arch Ophthalmol 2008;126(9):1191-1201
81. Goldstein DA, Godfrey DG, Hall A, et al. Intraocular pressure in patients with uveitis treated with fluocinolone acetonide implants. Arch Ophthalmol 2007;125(11):1478-1485
82. Available from: Http://www.bausch.com/en-US/downloads/ecp/pharma/general/ retisert-pkginsert.pdf [Last accessed 11 December 2011]
83. Taban M, Lowder CY, Kaiser PK. Outcome of fluocinolone acetonide implant (Retisert-) reimplantation for chronic noninfectious posterior uveitis. Retina 2008;28:1280-1288
84. Galor A, Margolis R, Kaiser PK, Lowder CY. Vitreous band formation and the sustained-release, intravitreal fluocinolone (Retisert) implant. Arch Ophthalmol 2007;125(6):836-838
85. Ufret-Vincenty RL, Singh RP, Lowder CY, Kaiser PK. Cytomegalovirus retinitis after fluocinolone acetonide (Retisert) implant. Am J Ophthalmol 2007;143(2):334-335
86. Clinical trial # NCT00502541 ClinicalTrials.gov. Available from: Http://www.clinicaltrial.gov/ct2/show/NCT00502541?term=fluocinolone +acetonide&rank=6 [Last accessed 11 December 2011]
87. Ramchandran RS, Fekrat S, Stinnett SS, Jaffe GJ. Fluocinolone acetonide sustained drug delivery device for chronic central retinal vein occlusion: 12-month results. Am J Ophthalmol 2008;146(2):285-291
88. Kane FE, Burdan J, Cutino A, Green KE. Iluvien: A new sustained delivery technology for posterior eye disease. Expert Opin Drug Deliv 2008;5(9):1039-1046
89. Alimera Sciences Immediate Release. 12-month safety and efficacy results from the first human pharmacokinetic study (PK Study) of Iluvien-. Atlanta, GA: 2009. Available from: Http://investor. alimerasciences.com/releasedetail.cfm? ReleaseID=458795
90. Clinical trial # NCT00490815 ClinicalTrials.gov. Available from: Http://www.clinicaltrial.gov/ct2/show/NCT00490815?term=fluocinolone +acetonide&rank=5 [Last accessed 11 December 2011]
91. Hainsworth DP, Pearson PA, Conklin JD, Ashton P. Sustained release intravitreal dexamethasone. J Ocul Pharmacol Ther 1996;12(1):57-63
92. Jaffe GJ, Pearson PA, Ashton P. Dexamethasone sustained drug delivery implant for the treatment of severe uveitis. Retina 2000;20(4):402-403
93. Kuppermann BD, Blumenkranz MS, Haller JA, et al. Dexamethasone DDS Phase II Study Group. Randomized controlled study of an intravitreous dexamethasone drug delivery system in patients with persistent macular edema. Arch Ophthalmol 2007;125(3):309-317
94. Haller JA, Bandello F, Belfort R Jr, et al. Ozurdex GENEVA Study Group. Dexamethasone intravitreal implant in patients with macular edema related to branch or central retinal vein occlusion twelve-month study results. Ophthalmology 2011;118(12):2453-2460
95. Lowder C, Belfort R Jr, Lightman S, et al. Ozurdex HURON Study Group. Dexamethasone intravitreal implant for noninfectious intermediate or posterior uveitis. Arch Ophthalmol 2011;129(5):545-553
96. Clinical trial # NCT01492400 ClinicalTrials.gov. Available from: Http://www.clinicaltrials.gov/ct2/show/NCT01492400?term=dexamethasone +and+diabetic+macular+edema&rank=12[Last accessed 21 April 2012]
97. Beeley NR, Stewart JM, Tano R, et al. Development, implantation, in vivo elution, and retrieval of a biocompatible, sustained release subretinal drug delivery system. J Biomed Mater Res A 2006;1576(4):690-698
98. Barnett PJ. Mathematical modeling of triamcinolone acetonide drug release from the I-vation intravitreal implant (a controlled release platform). Conf Proc IEEE Eng Med Biol Soc 2009;2009:3087-3090
99. Information available from Surmodics website, I-vation Sustained Drug Delivery System. Available from: Http://www.surmodics.com/pdf/ophthalmology. pdf [Last accessed 11 December 2011]
100. Eliott D, Dugel PU, Cantrill HL, et al. I-vation-TA: 15-month clinical results of the phase I safety and preliminary efficacy study [abstract 3501]. Poster presented at the Association for Research in Vision and Ophthalmology; 28 April -2 May 2008; Fort Lauderdale, FL.
101. Clinical trial # NCT00692614 ClinicalTrials.gov. Available from: Http://www.clinicaltrial.gov/ct2/show/NCT00692614?term=MK0140&rank=1 [Last accessed 11 December 2011]
102. Stepien KE, Eaton AM, Jaffe GJ, et al. Increased incidence of sterile endophthalmitis after intravitreal triamcinolone acetonide in spring 2006. Retina 2009;29(2):207-213
103. CATT Research Group. Martin DF, Maguire MG, Ying GS, et al. Ranibizumab and bevacizumab for neovascular age-related macular degeneration. N Engl J Med 2011;364(20):1897-1908